These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 9352252)
1. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and acetyl-N-Ser-Asp-Lys-Pro concentrations. Comte L; Lorgeot V; Volkov L; Allegraud A; Aldigier JC; Praloran V Eur J Clin Invest; 1997 Sep; 27(9):788-90. PubMed ID: 9352252 [TBL] [Abstract][Full Text] [Related]
2. Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats. Junot C; Nicolet L; Ezan E; Gonzales MF; Menard J; Azizi M J Pharmacol Exp Ther; 1999 Dec; 291(3):982-7. PubMed ID: 10565814 [TBL] [Abstract][Full Text] [Related]
3. Angiotensin I-converting enzyme and metabolism of the haematological peptide N-acetyl-seryl-aspartyl-lysyl-proline. Azizi M; Junot C; Ezan E; Ménard J Clin Exp Pharmacol Physiol; 2001 Dec; 28(12):1066-9. PubMed ID: 11903317 [TBL] [Abstract][Full Text] [Related]
4. Activity of acetyl-Ser-Asp-Lys-Pro (AcSDKP) on human hematopoietic progenitor cells in short-term and long-term bone marrow cultures. Jackson JD; Ozerol E; Yan Y; Ewel C; Talmadge JE J Hematother Stem Cell Res; 2000 Aug; 9(4):489-96. PubMed ID: 10982247 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of human bone marrow progenitors by the synthetic tetrapeptide AcSDKP. Guigon M; Bonnet D; Lemoine F; Kobari L; Parmentier C; Mary JY; Najman A Exp Hematol; 1990 Nov; 18(10):1112-5. PubMed ID: 2209766 [TBL] [Abstract][Full Text] [Related]
7. Catabolism of the hemoregulatory peptide N-Acetyl-Ser-Asp-Lys-Pro: a new insight into the physiological role of the angiotensin-I-converting enzyme N-active site. Rousseau-Plasse A; Lenfant M; Potier P Bioorg Med Chem; 1996 Jul; 4(7):1113-9. PubMed ID: 8831983 [TBL] [Abstract][Full Text] [Related]
8. Activity of acetyl-n-ser-asp-lys-pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Jackson JD; Yan Y; Ewel C; Talmadge JE Exp Hematol; 1996 Feb; 24(3):475-81. PubMed ID: 8599978 [TBL] [Abstract][Full Text] [Related]
9. In vitro effect of acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) analogs resistant to angiotensin I-converting enzyme on hematopoietic stem cell and progenitor cell proliferation. Gaudron S; Grillon C; Thierry J; Riches A; Wierenga PK; Wdzieczak-Bakala J Stem Cells; 1999; 17(2):100-6. PubMed ID: 10195570 [TBL] [Abstract][Full Text] [Related]
10. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Chisi JE; Briscoe CV; Ezan E; Genet R; Riches AC; Wdzieczak-Bakala J Br J Haematol; 2000 Jun; 109(3):563-70. PubMed ID: 10886205 [TBL] [Abstract][Full Text] [Related]
11. In vivo modifications of AcSDKP metabolism and haematopoiesis in mice treated with 5-fluorouracil and Goralatide. Comte L; Lorgeot V; Bignon J; Volkov L; Dupuis F; Wdzieczak-Bakala J; Praloran V Eur J Clin Invest; 1998 Oct; 28(10):856-63. PubMed ID: 9793000 [TBL] [Abstract][Full Text] [Related]
12. The tetrapeptide AcSDKP reduces the sensitivity of murine CFU-MK and CFU-GM progenitors to aracytine in vitro and in vivo. Aidoudi S; Guigon M; Drouet V; Caen JP; Han ZC Int J Hematol; 1998 Aug; 68(2):145-55. PubMed ID: 9803673 [TBL] [Abstract][Full Text] [Related]
13. [The hemoprotective effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP]. Han Z; Cai Y; Aidoudi S Zhonghua Xue Ye Xue Za Zhi; 1999 Jan; 20(1):33-5. PubMed ID: 11498842 [TBL] [Abstract][Full Text] [Related]
14. In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracil. Aidoudi S; Guigon M; Lebeurier I; Caen JP; Han ZC Br J Haematol; 1996 Sep; 94(3):443-8. PubMed ID: 8790139 [TBL] [Abstract][Full Text] [Related]
15. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors. Massé A; Ramirez LH; Bindoula G; Grillon C; Wdzieczak-Bakala J; Raddassi K; Deschamps de Paillette E; Mencia-Huerta JM; Koscielny S; Potier P; Sainteny F; Carde P Blood; 1998 Jan; 91(2):441-9. PubMed ID: 9427696 [TBL] [Abstract][Full Text] [Related]
16. The tetrapeptide AcSDKP, an inhibitor of the cell-cycle status for normal human hematopoietic progenitors, has no effect on leukemic cells. Bonnet D; Césaire R; Lemoine F; Aoudjhane M; Najman A; Guigon M Exp Hematol; 1992 Feb; 20(2):251-5. PubMed ID: 1544396 [TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: differential inhibition of acetyl-ser-asp-lys-pro and angiotensin I hydrolysis. Junot C; Menard J; Gonzales MF; Michaud A; Corvol P; Ezan E J Pharmacol Exp Ther; 1999 Jun; 289(3):1257-61. PubMed ID: 10336514 [TBL] [Abstract][Full Text] [Related]
18. Functional consequences of angiotensin-converting enzyme gene polymorphism on N-acetyl-Ser-Asp-Lys-Pro degradation and angiotensin II production. Azizi M; Junot C; Ezan E; Hallouin MC; Guyene T; Ménard J J Mol Med (Berl); 2002 Aug; 80(8):492-8. PubMed ID: 12185449 [TBL] [Abstract][Full Text] [Related]
19. Inhibitory action of the peptide AcSDKP on the proliferative state of hematopoietic stem cells in the presence of captopril but not lisinopril. Chisi JE; Wdzieczak-Bakala J; Riches AC Stem Cells; 1997; 15(6):455-60. PubMed ID: 9402658 [TBL] [Abstract][Full Text] [Related]
20. The physiological role of the endogenous colony forming units-spleen (CFU-S) inhibitor acetyl-N-Ser-Asp-Lys-Pro (AcSDKP). Frindel E; Monpezat JP Leukemia; 1989 Oct; 3(10):753-4. PubMed ID: 2779291 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]